CARDAMYST Nasal Spray Now Available on Express Scripts Formularies

Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives Decision Expands Coverage to National Preferred Formulary Commercially Insured Lives

Milestone Pharmaceuticals has reported a significant development regarding its product CARDAMYST (etripamil) Nasal Spray, a medication aimed at providing rapid relief for patients experiencing paroxysmal supraventricular tachycardia (PSVT). The announcement indicates that CARDAMYST is now accessible through Express Scripts' Commercial National Formularies. This is a pivotal step as it could greatly enhance patient access to this innovative treatment option.

The launch of CARDAMYST through Express Scripts means that healthcare providers can now prescribe this nasal spray more widely, benefiting patients who require immediate intervention to manage their PSVT episodes. This formulation is designed for quick administration, providing potential benefits over traditional oral medications that may take longer to take effect.

Milestone's strategic move to partner with Express Scripts is indicative of the company’s commitment to improve patient outcomes, ensuring that essential medications are easily attainable for those in need. With the growing incidence of cardiac conditions like PSVT, having a convenient and effective treatment option is critical.

The availability of CARDAMYST in the Express Scripts formularies marks an important advancement in the company's efforts to expand its market reach and foster awareness of this therapy among both healthcare providers and patients.

Milestone Pharmaceuticals is dedicated to addressing unmet needs in cardiovascular care, and this initiative reflects its ongoing mission to enhance health outcomes through innovative therapies. The response from the medical community and patients alike will be crucial in shaping the future of etripamil as a go-to option for PSVT management.

In summary, the announcement of CARDAMYST's availability marks a milestone not only for Milestone Pharmaceuticals but also for the wider healthcare community, reinforcing the importance of efficient treatment options for patients experiencing PSVT.